Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: An international multicentre analysis
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 2,42 MB, PDF-dokument
Methods: We performed a retrospective cohort analysis of patients with LGSC who had had primary surgery and had overall survival data available. We performed univariate and multivariate analyses of progression-free survival and overall survival, and generated Kaplan–Meier survival curves.
Results: Of the 707 patients with LGSC, 680 (96.2%) had available overall survival data. The patients’ median age overall was 54 years. Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had stage II, 395 (59.9%) had stage III, and 44 (6.7%) had stage IV. Of the 377 patients with surgical data, 200 (53.0%) had no visible residual disease. Of the 361 patients with chemotherapy data, 330 (91.4%) received first-line platinum-based chemotherapy. The median follow-up duration was 5.0 years. The median progression-free survival and overall survival were 43.2 months and 110.4 months, respectively. Multivariate analysis indicated a statistically significant impact of stage and residual disease on progression-free survival and overall survival. Platinum-based chemotherapy was not associated with a survival advantage.
Conclusion: This multicentre analysis indicates that complete surgical cytoreduction to no visible residual disease has the most impact on improved survival in LGSC. This finding could immediately inform and change practice.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | CMAJ. Canadian Medical Association Journal |
| Vol/bind | 66 |
| Udgave nummer | 3 |
| Sider (fra-til) | E310-E320 |
| Antal sider | 11 |
| ISSN | 0820-3946 |
| DOI | |
| Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:
The Ovarian Cancer Association Consortium is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07). Funding for individual studies: AUS: the Australian Ovarian Cancer Study Group was supported by the U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, the National Health and Medical Research Council of Australia (APP199600, APP400413 and APP400281), Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania, and Cancer Foundation of Western Australia (Multi-State Applications 191, 211 and 182). The Australian Ovarian Cancer Study gratefully acknowledges additional support from Ovarian Cancer Action (UK), Ovarian Cancer Australia and the Peter MacCallum Foundation. BAV: ELAN Funds of the University of Erlangen-Nuremberg. BEL: National Kankerplan. CNI: Instituto de Salud Carlos III (PI 12/01319) and Ministerio de Economía y Competitividad (SAF2012). GER: German Federal Ministry of Education and Research, Programme of Clinical Biomedical Research (01 GB 9401) and the German Cancer Research Center (DKFZ). HAW: U.S. National Institutes of Health (R01-CA58598, N01-CN-55424 and N01-PC-67001). HJO: Intramural funding and the Rudolf-Bartling Foundation; HOP: Department of Defense (DAMD17-02-1-0669) and National Cancer Institute (K07-CA080668, R01-CA95023, P50-CA159981, MO1-RR000056 and R01-CA126841). JPN: Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare. KRA: This study was partially supported by grant HI16C1127; 0920010 from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea. LAX: American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN) and the National Center for Advancing Translational Sciences (grant UL1TR000124). MAC: National Institutes of Health (R01-CA122443, P30-CA15083 and P50-CA136393), Mayo Foundation, Minnesota Ovarian Cancer Alliance, Fred C. and Katherine B. Andersen Foundation and Fraternal Order of Eagles. MAL: funding for this study was provided by research grant R01-CA61107 from the National Cancer Institute, research grant 94 222 52 from the Danish Cancer Society and the Mermaid I project. MAY: National Institutes of Health (R01-CA122443, P30-CA15083 and P50-CA136393), Mayo Foundation, Minnesota Ovarian Cancer Alliance and Fred C. and Katherine B. Andersen Foundation. MOF: H. Lee Moffitt Cancer Center & Research Institute, Merck Pharmaceuticals, the state of Florida, Hillsborough County and the city of Tampa. NCO: National Institutes of Health (R01-CA76016) and Department of Defense (DAMD17-02-1- 0666). NEC: National Institutes of Health (R01-CA54419 and P50-CA105009) and Department of Defense (W81XWH-10-1-02802). NJO: National Cancer Institute (NIH-K07 CA095666, R01-CA83918, NIH-K22-CA138563 and P30- CA072720) and Cancer Institute of New Jersey. NOR: Helse Vest, The Norwegian Cancer Society, The Research Council of Norway. NTH: Radboud University Medical Centre. OPL: National Health and Medical Research Council of Australia (APP1025142) and Brisbane Women's Club. ORE: OHSU Foundation. POL: Intramural Research Program of the National Cancer Institute. PVD: Canadian Cancer Society and Cancer Research Society GRePEC Program. RBH: National Health and Medical Research Council of Australia. SIS: The Sister Study (SISTER) is supported by the Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health (grants Z01-ES044005 and Z01-ES049033). SRO: Cancer Research UK (C536/A13086, C536/A6689) and Imperial Experimental Cancer Research Centre (C1312/A15589). STA: National Institutes of Health (grants U01 CA71966 and U01 CA69417). TBO: National Institutes of Health (R01-CA106414-A2), American Cancer Society (CRTG-00- 196-01-CCE), Department of Defense (DAMD17-98-1-8659) and Celma Mastery Ovarian Cancer Foundation. UCI: the UCI ovarian cancer study is supported by the National Cancer Institute, National Institutes of Health (grant R01-CA058860) and Lon V Smith Foundation (grant LVS-39420). UHN: Princess Margaret Cancer Centre Foundation - Bridge for the Cure. UKR: Cancer Research UK (C490/A6187) and UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge. WMH: National Health and Medical Research Council of Australia (Enabling Grants ID 310670 and ID 628903), Cancer Institute NSW (Grants 12/RIG/1- 17 and 15/RIG/1-16), NSW Ministry of Health, AstraZeneca Pty, Medical Research Future Fund (Australia), Rivkin Center and University of Sydney. WOC: National Science Centre (N N301 5645 40) and Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw.
Funding Information:
Funding: The Ovarian Cancer Association Consortium is supported
Funding Information:
by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07).
Publisher Copyright:
© 2023 Canadian Medical Association. All rights reserved.
ID: 363360972